Aktiechat - investeringstips

	22/2 16:05 af jkj	What dollar rate is the basis for your 2018 forecast.
	22/2 16:05 af Jan Van de Winkel	and further visibility on Genmab's worldclass pipeline and clinical programs at 2018 CMD aimed for September.
	22/2 16:04 af Jan Van de Winkel	and data in solid tumors should come in the 2H of this year....
	22/2 16:04 af Jan Van de Winkel	expected approval in Frontline MM DVMP... US likely first, and in EU 2H, and filing in Japan for this combination...
	22/2 16:03 af Jan Van de Winkel	clinical data from Tisotumab vedotin in other solid cancers, (in 2H), and early clinical data HuMax-AXL-ADC (2H)...
	22/2 16:02 af Jan Van de Winkel	Events: readout from two key Phase 3 studies in Frontline MM, Maia and Cassiopeia....
	22/2 16:01 af Jan Van de Winkel	Guidance for 2018 - midpoints: revenue 2.9 bn DKK, expenses 1.5 bn DKK and op income 1.4 bn DKK. Darzalex sales midpoint 2.15 bn USD, royalties DKK 1.75 bn.
	22/2 16:00 af Helge Larsen/PI-redaktør	The stock market appreciates Genmab's guidance for 2018 today. What do you expect in key figures and important events this year?
	22/2 15:59 af Jan Van de Winkel	and finally approvals in EU; US and Japan for Darzalex and an IND filed in RA by Janssen.
	22/2 15:59 af Jan Van de Winkel	two more INDs filed for Genmab proprietary programs, DuoBody-CD3xCD20 and HexaBody-DR5/DR5....
	22/2 15:58 af Jan Van de Winkel	and encouraging ph I/II data in cervical cancer with Tisotumab vedotin and announcement of a potential pivotal trial....
	22/2 15:58 af Jan Van de Winkel	great results in key frontline ph 3 Alcyone study....
	22/2 15:58 af Jan Van de Winkel	In terms of the events and progress. Darzalex sales continued rapidly and passed blockbuster status....
	22/2 15:57 af Jan Van de Winkel	Key figures: 2017 revenue up 30% - expenses up 34% and Op income up 28%. A record revenue level for Genmab, highest ever Op Income and highest ever cash position for the company.
	22/2 15:56 af Helge Larsen/PI-redaktør	First of all let me congratulate on the great results for 2017 . Can you give us a short-term update on key figures and important events?
	22/2 15:56 af Jan Van de Winkel	Looking forward to the first questions.
	22/2 15:55 af Helge Larsen/PI-redaktør	Good afternoon. Welcome to Q&A here on ProInvestor.com. We are very happy to have you back here and ready to answer questions from our investors.
	22/2 15:55 af Jan Van de Winkel	We are ready to start when you are. This is Jan van de Winkel, David Eatwell and Judith Klimovsky here.
	22/2 15:53 af Helge Larsen/PI-redaktør	Yes. :-)
	22/2 15:53 af Jan Van de Winkel	In a moment we will be ready. Are you ready for us?